News

FDA Tracks Fake Avastin to Foreign Supply Distributed in U.S.


 

Medical practices that have obtained unapproved products from foreign sources, in particular from Volunteer Distribution and/or QSP, should stop using them and contact the FDA. These products should be retained and securely stored.

To report suspect counterfeit products and other suspect unapproved products obtained from Volunteer Distribution or QSP/Montana Health Care Solutions or other sources: Call FDA’s Office of Criminal Investigations (OCI) at 800-551-3989, or visit OCI’s website.

For information about this counterfeit medicine, see Roche’s statement.

Click here for more information about counterfeit medicines found in the United States.

Pages

Recommended Reading

NICE Issues Early 'No' on Abiraterone
MDedge Hematology and Oncology
MDV3100 Cuts Risk of Death in Advanced Prostate Cancer
MDedge Hematology and Oncology
ALSYMPCA Trial: Radium-223 Prolongs Life in Some Prostate Cancers
MDedge Hematology and Oncology
Kidney Cancer Patients May Need Higher Axitinib Dose
MDedge Hematology and Oncology
FDA Questions Earlier Denosumab Use in Prostate Cancer
MDedge Hematology and Oncology
FDA Panel Rejects Denosumab Against Bone Metastasis in Prostate Cancer
MDedge Hematology and Oncology
Mild CKD Ups Risks of Renal, Urothelial Cancers
MDedge Hematology and Oncology
Everolimus Shrinks Angiomyolipomas from Tuberous Sclerosis Complex
MDedge Hematology and Oncology
Costs Don't Always Match Outcomes of Prostate Cancer Treatments
MDedge Hematology and Oncology
Vitamin E Supplements Linked to Increase in Prostate Cancer Risk
MDedge Hematology and Oncology